Open AccessFungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors
Author(s) -
Marissa A. Zarakas,
Jigar V. Desai,
Georgios Chamilos,
Michail S. Lionakis
Publication year - 2019
Publication title -
current fungal infection reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.413
H-Index - 24
eISSN - 1936-377X
pISSN - 1936-3761
DOI - 10.1007/s12281-019-00343-9
Subject(s) - ibrutinib , bruton's tyrosine kinase , antifungal , tyrosine kinase , risk stratification , medicine , immunology , intensive care medicine , leukemia , chronic lymphocytic leukemia , dermatology , receptor
Small molecule kinase inhibitors (SMKIs) have revolutionized the management of malignant and autoimmune disorders. Emerging clinical reports point toward an increased risk for invasive fungal infections (IFIs) in patients treated with certain SMKIs. In this mini-review, we highlight representative examples of SMKIs that have been associated with or are expected to give rise to IFIs.